These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 17632537

  • 1. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL, Iyasu S.
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [Abstract] [Full Text] [Related]

  • 2. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
    Breslow LH.
    Harvard J Legis; 2003 Aug; 40(1):133-93. PubMed ID: 16594116
    [Abstract] [Full Text] [Related]

  • 3. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
    Rivera DR, Hartzema AG.
    Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
    [Abstract] [Full Text] [Related]

  • 4. Stimulation programs for pediatric drug research--do children really benefit?
    Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF, Burggraaf J.
    Eur J Pediatr; 2007 Aug; 166(8):849-55. PubMed ID: 17225950
    [Abstract] [Full Text] [Related]

  • 5. FDA update.
    Katz R.
    Epilepsy Res; 2006 Jan; 68(1):85-94. PubMed ID: 16377143
    [Abstract] [Full Text] [Related]

  • 6. Pediatric marketing exclusivity--as altered by the Best Pharmaceuticals for Children Act of 2002.
    Cooper KJ.
    Food Drug Law J; 2002 Jan; 57(3):519-44. PubMed ID: 12710409
    [No Abstract] [Full Text] [Related]

  • 7. Pediatric research: coming of age in the new millennium.
    Milne CP.
    Am J Ther; 1999 Sep; 6(5):263-82. PubMed ID: 11329108
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R, Wyeth J, Chen M, Cope JU.
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective.
    Bernhardt MB, Lindsay H, Allen-Rhoades W, Foster JH.
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28871. PubMed ID: 33381908
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Drug-review deadlines and safety problems.
    Carpenter D, Zucker EJ, Avorn J.
    N Engl J Med; 2008 Mar 27; 358(13):1354-61. PubMed ID: 18367738
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FDA reform signed into law. Food and Drug Administration.
    James JS.
    AIDS Treat News; 1997 Dec 05; (No 284):6-7. PubMed ID: 11364915
    [Abstract] [Full Text] [Related]

  • 18. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ, David M.
    Food Drug Law J; 2009 Dec 05; 64(1):115-48. PubMed ID: 19998743
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.